title: Production of recombinant large proneurotensin/neuromedin N-derived peptides and characterization of their binding and biological activity.
abstract: Proneurotensin/neuromedin N (pro-NT/NN) is the common precursor of two biologically active related peptides, neuromedin N (NN) and neurotensin (NT). It undergoes a tissue-specific processing leading to the formation in some tissues and cancer cell lines of large peptides ending with the NT (large NT) or NN (large NN) sequence. In this study, we prepared and purified high amounts of recombinant large NT and large NN using the Drosophila S2 cell expression system. The binding and pharmacological properties of recombinant large peptides were characterized and compared to those of NT and NN using either COS cells transfected with the human subtype-1 NT receptor (hNTS1) or the human colon adenocarcinoma HT29 cell line that endogenously expresses hNTS1. Furthermore, the metabolic stability of the large peptides, when exposed to HT29 cells, was compared to that of NT and NN. Both large NT and large NN were able to bind to and activate hNTS1 with potencies that were approximately 10 times lower than that of their small counterpart. In addition, the large forms proved to be far less sensitive to degradation than the small peptides. Taken together, these data suggest that the large forms might represent endogenous, long-lasting activators of hNTS1 in a number of physiopathological situations.
authors.affiliation: Institut de Pharmacologie Moléculaire et Cellulaire, CNRS UMR 6097, Sophia Antipolis 660 Route des Lucioles, Valbonne, 06560, France.
authors.forename: Claire
authors.initials: C
authors.lastname: Friry
authors.forename: Sylvain
authors.initials: S
authors.lastname: Feliciangeli
authors.forename: Françoise
authors.initials: F
authors.lastname: Richard
authors.forename: Patrick
authors.initials: P
authors.lastname: Kitabgi
authors.forename: Carole
authors.initials: C
authors.lastname: Rovere
mesh_terms: D000818:Animals; D019556:COS Cells; D002460:Cell Line; D004330:Drosophila; D004355:Drug Stability; D006801:Humans; D007295:Inositol Phosphates / Q000096:biosynthesis; D009496:Neurotensin / Q000096:biosynthesis* / Q000235:genetics / Q000494:pharmacology; D011485:Protein Binding; D011498:Protein Precursors / Q000096:biosynthesis* / Q000235:genetics / Q000494:pharmacology; D011499:Protein Processing, Post-Translational; D018028:Receptors, Neurotensin / Q000187:drug effects / Q000235:genetics / Q000378:metabolism; D011994:Recombinant Proteins / Q000096:biosynthesis / Q000235:genetics / Q000494:pharmacology
chemical_list: D007295:Inositol Phosphates; D011498:Protein Precursors; D018028:Receptors, Neurotensin; D011994:Recombinant Proteins; C052457:neuromedin N precursor; C114036:neurotensin type 1 receptor; C411471:proneurotensin; D009496:Neurotensin